AAMU
STOK icon

Amundi Asset Management US’s Stoke Therapeutics STOK Stock Holding History

Amundi Asset Management US’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$29K – 1699
2019
Q2 		$29K Buy
+1,000
New +$26.9K ﹤0.01% 1610

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Amundi Asset Management US's STOK Position: Q3 2019 in Review

Amundi Asset Management US sold out of Stoke Therapeutics (STOK) in Q3 2019, closing a stake of 1,000 shares — an estimated $29K sold.

Amundi Asset Management US first reported a position in STOK in Q2 2019 and held it in 1 quarter. The position peaked at $29K in Q2 2019. 53 funds tracked by Wall St. Rank hold STOK as of Q3 2019.

  • Amundi Asset Management US reported no remaining Stoke Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 1,000 Stoke Therapeutics shares in Q3 2019, an estimated $29K.
  • Amundi Asset Management US first reported a position in Stoke Therapeutics in Q2 2019 and held it in 1 quarter.
  • Amundi Asset Management US's Stoke Therapeutics position peaked at $29K in Q2 2019.
  • 53 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2019.

Based on Amundi Asset Management US's 13F filing for Q3 2019, filed 14 Nov 2019.